GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Notes Receivable

Nyrada (ASX:NYR) Notes Receivable : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Notes Receivable?

Nyrada's Notes Receivable for the quarter that ended in Dec. 2024 was A$0.00 Mil.


Nyrada Notes Receivable Historical Data

The historical data trend for Nyrada's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Notes Receivable Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Nyrada Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Nyrada Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Nyrada Notes Receivable Related Terms

Thank you for viewing the detailed overview of Nyrada's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyrada Business Description

Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada Headlines

No Headlines